Case 1 – Successful resection after FOLFIRI plus cetuximab therapy for unresectable colorectal cancer with multiple liver metastases

 

Authors

  • Anna Nappi Department of Abdominal Oncology, Istituto Nazionale Tumori di Napoli “G. Pascale” IRCCS, National Cancer Institute, Naples, Italy.
  • Carmela Romano Department of Abdominal Oncology, Istituto Nazionale Tumori di Napoli “G. Pascale” IRCCS, National Cancer Institute, Naples, Italy.
  • Gugliemo Nasti Department of Abdominal Oncology, Istituto Nazionale Tumori di Napoli “G. Pascale” IRCCS, National Cancer Institute, Naples, Italy.
  • Fotios Loupakis Istituto Oncologico Veneto, IRCCS Padua, Italy

DOI:

https://doi.org/10.19156/cbn.2017.0057

Keywords:

left colorectal cancer, liver metastasis, multidisciplinary approach, conversion chemotherapy

Abstract

This case report describes the outcome of a multidisciplinary approach which allowed successful resection in a patient diagnosed with unresectable colorectal cancer. The patient was a 66-year-old man with no important comorbidities. His main complaint was abdominal pain. The patient received a diagnosis of moderate differentiated sigmoid colon adenocarcinoma, RAS and BRAF wild type. Multiple liver metastases were detected. Conversion therapy was given and the patient received 8 therapy courses with FOLFIRI plus cetuximab. Grade 1 diarrhea and grade II skin toxicity were observed as adverse effects of the chemotherapy. The size of the tumor was reduced and the tumor was resected performing left colectomy, segment liver VI resection and performing intraoperative thermos-ablation with microwave. No recurrence was observed at 6 months after surgery.

Downloads

Published

2017-12-15

How to Cite

1.
Nappi A, Romano C, Nasti G, Loupakis F. Case 1 – Successful resection after FOLFIRI plus cetuximab therapy for unresectable colorectal cancer with multiple liver metastases:  . CBN [Internet]. 2017 Dec. 15 [cited 2024 Jul. 3];5(3):30-5. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/193

Issue

Section

Meet the expert